



Company Overview

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona's lead clinical program is EB-101, its investigational autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development. The Company's development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need.

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 1 2024, 8:30 AM EDT

Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections

Mar 18 2024, 7:30 AM EDT

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 5 2024, 7:30 AM EST

Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	212.28m
Last Price	\$7.76
52-Week	\$2.77 - \$9.01

04/16/2024 04:00 PM EDT

Investor Relations

ir@abeonatherapeutics.com

Management Team

Vishwas Seshadri, Ph.D., M.B.A.

Chief Executive Officer, Director

Dmitriy Grachev, M.D., Ph.D.

Chief Medical Officer

Brian Kevany, Ph.D.

SENIOR VICE PRESIDENT, CHIEF TECHNICAL OFFICER & CHIEF SCIENTIFIC OFFICER

Joseph Vazzano

Chief Financial Officer

Carl Denny

Senior Vice President, Regulatory Affairs

Greg Gin

Vice President, Investor Relations and Corporate Communications

Alison Hardgrove

Vice President, Human Resources

Amanda Moore, MSHS

Vice President, Program Leadership and Clinical Operations

Brendan O'Malley, J.D., Ph.D.

Senior Vice President, General Counsel

Madhav Vasanthavada, Ph.D., M.B.A.

Senior Vice President, Chief Commercial Officer & Head of Business Development

Abeona Therapeutics Inc.

6555 Carnegie Avenue
4th Floor
Cleveland, OH 44103

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.